Business UpdateJun 12, 2026, 07:06 AM
Dianthus Therapeutics Updates Corporate Presentation with Trial Data
AI Summary
Dianthus Therapeutics, Inc. has released an updated corporate presentation detailing interim responder analysis data from its Phase 3 CAPTIVATE trial for claseprubart in CIDP. The presentation also highlighted positive Phase 2 MaGic trial results for claseprubart in gMG. The company reported approximately $1.2 billion in cash as of March 31, 2026, providing a runway into 2030. An early 'GO' decision was made for the CAPTIVATE trial based on interim responder analysis.
Key Highlights
- Dianthus Therapeutics posted an updated corporate presentation on June 11, 2026.
- The presentation included interim responder analysis data for the first 40 patients in Part A of the Phase 3 CAPTIVATE trial for claseprubart in CIDP.
- Claseprubart is an investigational agent for chronic inflammatory demyelinating polyneuropathy (CIDP) and generalized myasthenia gravis (gMG).
- The company has approximately $1.2B in cash and cash equivalents as of March 31, 2026, with runway expected into 2030.
- Phase 2 MaGic trial results for claseprubart in gMG showed rapid and robust improvements.
- The CAPTIVATE trial for CIDP announced an early 'GO' decision in March 2026 based on interim responder analysis.
Price Impact
More from DNTH